FDA’s Statement on Proposed Hydrocodone Reclassification

  • This page as PDF

Summary

On October 24, Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at FDA, issued a statement indicating the Agency's intent to recommend reclassifying hydrocodone combination products from Schedule III to Schedule II products.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

Her recommendation is in response to the DEA’s 2009 request to HHS to change the classification of hydrocodone combination products, hoping to address widespread abuse of opioid drug products in the U.S. Such changes will likely enforce much stricter security controls for patients and prescribers of hydrocodone, as well as causing manufacturers and distributors to comply with much stricter DEA-mandated Schedule II storage and security requirements.

Assuming the DEA follows FDA’s recommendations, stricter scheduling requirements will put the cost burden on manufacturers and some distributors, as many will need to devote additional resources to meeting DEA requirements.

FDA says they will submit a National Institute on Drug Abuse-approved formal recommendation package to HHS by December 2013.

Webinar | Valuing the Patient Perspective: Patient-Centered HTA

On April 25 at 1 PM, this expert panel will address the challenge of integrating patient perspectives into value assessments, discussing implications for evidence strategy, health equity, caregiver involvement, and downstream impacts on care delivery. Learn More
Register Now

Sign up to receive more insights about Regulatory Strategy and FDA Policy
Please enter your email address to be notified when new Regulatory Strategy and FDA Policy insights are published.

Back To Top